Formulation Development Applications & Studies

  1. Comparing Immunotherapy, Standard Treatment, And Therapy On MC38 Colon Cancer 3/28/2025

    Our findings highlight the potential of combining irinotecan with immune checkpoint inhibitors in MC38 tumor models, demonstrating a promising approach for future research and therapeutic strategies.

  2. Reliable And Reproducible Preclinical Rodent Models Of MASH 3/28/2025

    Our preclinical studies highlight Elafibranor's potential in treating MASH and its progression to hepatocellular carcinoma, warranting further development.

  3. Optimizing Upstream Process Development To Increase mAb Titers 3/28/2025

    Uncover how we were able to help a client develop an efficient upstream process for a novel monoclonal antibody (mAb), resulting in a more than 100% increase in titers.

  4. Tag-Free Expression, in vivo Maturation, And Protein Purification 3/28/2025

    Optimizing recombinant expression and scalable purification strategies can help accelerate the production of challenging proteins, enabling successful program initiation and advancing pipelines.

  5. Introducing SUPR 3/28/2025

    Validating the performance of Getinge 50L and 250L single-use bioreactors alongside smaller-scale systems can optimize production processes and ensure scalability for CHO cell cultivation.

  6. A Translational Mouse Model For Non-Genetic Heterotopic Ossification 3/28/2025

    Reproducing the thermal lesion/tenotomy-induced mouse model can help overcome the challenge of unpredictable heterotopic ossification localization and enable the development of targeted interventions.

  7. A Comparative Efficiency Analysis Of Commercial Transfection Reagents In HEK 293 Cells 3/27/2025

    This study presents a detailed comparative analysis of the efficiency, viability, and cytotoxic effects of four widely used transfection reagents on Human Embryonic Kidney 293 (HEK293) cells.

  8. Bleomycin-Induced Scleroderma Mouse Model For Preclinical Testing 3/27/2025

    Get an in-depth overview of the bleomycin-induced scleroderma model, detailing its key specifications and presenting significant findings observed following bleomycin administration in study animals.

  9. Preclinical Evaluation Of Novel Drug Candidates Against SLE In NZB/W F1 Mouse Models 3/27/2025

    Explore how the well-established NZB/W F1 mouse model enables the evaluation of novel anti-SLE therapeutics, providing critical insights into disease mechanisms and treatment efficacy.

  10. DSS-Induced IBD Mouse Model For Preclinical Drug Screening 3/27/2025

    Leverage our chemically induced murine model of Inflammatory Bowel Disease to accelerate your research on IBD and explore potential therapeutic interventions.